SCHEMBL7253116

SCHEMBL7253116

COc1ccc(C(=O)C(=CN(C)C)C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.57
CYP11B2 P19099 2/20 0.57
ALDH1A1 P00352 2/20 0.57
RAB9A P51151 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CES2 O00748 2/20 0.56
CES1 P23141 2/20 0.56
MAPT P10636 2/20 0.51
HPGD P15428 1/20 0.51
CA1 P00915 4/20 0.50
CA2 P00918 4/20 0.50
GAA P10253 1/20 0.50
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
PARP1 P09874 1/20 0.44
PARP10 Q53GL7 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
PARP4 Q9UKK3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253109 1.00 CYP11B1 (0.57) CYP11B1CYP11B2ALDH1A1RAB9AKMT2A
SCHEMBL7377209 0.87 CYP11B1 (0.57) CYP11B1CYP11B2ALDH1A1RAB9AKMT2A
SCHEMBL4291901 0.81 RAB9A (0.48) ALDH1A1RAB9AKMT2ASMN1; SMN2CES2
SCHEMBL4291907 0.81 RAB9A (0.48) ALDH1A1RAB9AKMT2ASMN1; SMN2CES2
SCHEMBL11389643 0.81 CYP11B1 (0.51) CYP11B1CYP11B2ALDH1A1RAB9AKMT2A
SCHEMBL2733267 0.80 CES2 (0.60) ALDH1A1RAB9AKMT2ACES2CES1
SCHEMBL5904300 0.80 CES2 (0.60) CYP11B1CYP11B2ALDH1A1RAB9AKMT2A
SCHEMBL5904302 0.80 CES2 (0.60) CYP11B1CYP11B2ALDH1A1RAB9AKMT2A
SCHEMBL10997616 0.80 CES2 (0.60) CYP11B1CYP11B2ALDH1A1RAB9AKMT2A
SCHEMBL2733268 0.80 CES2 (0.60) ALDH1A1RAB9AKMT2ACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003030909-A1 2- AND 4-AMINOPYRIMIDINES N-SUBSTTITUDED BY A BICYCLIC RING FOR USE AS KINASE INHIBITORS IN THE TREATMENT OF CANCER BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-17 WO disclosed